Consolidated Financial Results for the Year Ended March 31, 2025 (FY2024)

from the beginning

Consolidated Financial Results for the Year Ended March 31, 2025 (FY2024)

Financial Results Summary for FY2024

• FY2024 Financial Results and Highlights

• Consolidated Statements of Income/Net Sales by Business Segment

• Consolidated Net Sales by Business Segment

• Sales of Main Products (Pharmaceutical Business)

• Sales by Major Business Field (Animal Health Business)

• Analysis of FY2024 Operating Profit (vs FY2023)

• Consolidated Balance Sheet

• Consolidated FY2025 Performance Forecast

• Forecast of FY2025 Operating Profit (vs FY2024)

• Capital Expenditures, Depreciation, and R&D Expenses

About Action to Implement Management That Is Conscious of Cost of Capital and Share Price

• Efforts to swiftly achieve a PBR (price-to-book ratio) of above 1x, and trends in PBR and ROE

• Detail of Initiatives 1) Growth Strategy (Optimization of Cash Allocation)

• Detail of Initiatives 2) Strengthen Shareholder Returns

• Cross-Shareholdings Reduction

• Detail of Initiatives 3) Strengthen IR activities

Overview of FY2024 Initiatives for FY2025

Overview of FY2024 Review of the 4th year of the Medium-Term Management Plan

• The Goals of the Medium-Term Management Plan 2025

• Medium-Term Management Plan 2025 Summary of the 4th Year and the Target for Last year

• 7 strategies - Results in the 4th year of the Medium-Term Plan

• Mission for the final year of Medium-Term Management Plan 2025

ASKA Pharmaceutical Co., Ltd.

■Main Initiatives Specialty Areas

• Our Ob/Gyn Pharmaceutical Products by Life Stage

• Growth Driver - RELUMINA (Uterine Fibroids/Endometriosis Agent)

• LEP Formulation Market Continues to Expand

• Contribute to Meeting Unmet Medical Needs through RIFXIMA

• A Leading Company for Thyroid Treatment

• About Switch to OTC Use of Emergency Contraceptive Pill “NORLEVO”

■Main Initiatives Development Pipeline

• Pipeline

• Overview of Main Ob/Gyn Pipeline (as of May 16, 2025)

• Strengthening Drug Discovery Infrastructure

■Main Initiatives Overseas Business Development

• Overseas Business Policy

ASKA Animal Health Co., Ltd.

• ASKA Animal Health - Current Plan and Sales Composition Ratio

• ASKA Animal Health - Priority initiative and field-specific activity status

ASKA Pharma Medical Co., Ltd.

• ASKA Pharmaceutical Medical - Priority initiatives

Overseas Business Development

• Overseas Business Policy

• High-growth Markets - Moving into Vietnam

• Overview of Hataphar

• Efforts toward a Drug Bidding System and New Factory Operations

• Hataphar - The Next Step

• High-growth markets - Moving into the Philippines

• Collaborate with MedChoice of the Philippines

• Vision for overseas business

• ASKA Pharmaceutical Holdings -Group Strengths -

• Become a Total Healthcare Company with a Strong Foundation as a Specialty Pharma Company

• ASKA Pharmaceutical Holdings Group Corporate Message

Forward-looking Statements

Appendix

• Sales Ratio by Area and Sales Proportion of Brand-name Drugs(Slide only)

• ASKA Pharmaceutical: Business Review of the Past 15 Years (Consolidated)(Slide only)

• Net Sales/Operating Profit by Quarter (Past Actual)(Slide only)

• Sales Trend in ASKA Pharma's Ob/Gyn Products(Slide only)

• Trends in the Ob/Gyn Market(Slide only)

• Increase in the Number of Menstrual Cycles due to Changes in Life Events(Slide only)

• Number of Uterine Fibroids/Endometriosis/Dysmenorrhea Patients(Slide only)

• Estimated Number of Patients in Gynecological Diseases (in-house estimates from external data)(Slide only)

• Uterine Fibroids/Endometriosis Market(Slide only)

• Contributions in Around-The-Pill field(Slide only)

• RIFXIMA Related Topic: Activities to Propose Early Diagnosis/Treatment of Complications of Cirrhosis(Slide only)

• Outcomes of Thyroid Awareness Activities(Slide only)

• Ion Channel Drug Discovery (New Core Technologies)(Slide only)

• About Polycystic Ovary Syndrome (PCOS)(Slide only)

• Vietnamese and Philippine Pharmaceutical Markets(Slide only)

• Social Contribution Activities: Health Lab Mint+ for Women's Health(Slide only)

• Contribution to ESG 11 Material Issues and Women's Health(Slide only)

• Human Capital Initiatives(Slide only)

• Initiatives/External Evaluation(Slide only)

Inquiries